Humacyte Announces Presentation by Principal Investigator Highlighting Clinical Experience with HAVs at Vascular Access Society of the Americas 2021 Spring Conference -- HAV performance in the clinical setting as an arte

Announces Presentation by Principal Investigator Highlighting Clinical Experience with HAVs at Vascular Access Society of the Americas

2021 Spring Conference

HAV performance in the clinical setting as an arteriovenous reconstruction underscores the

potential for use as vascular access conduits

for dialysis patients --

N.C. - May 22, 2021 - Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable

bioengineered human tissue at commercial scale, today announced that results from clinical studies of the human acellular vessels (HAV)

for arteriovenous (AV) access in hemodialysis were presented at the Vascular Access Society of the Americas (VASA) 2021 Spring Virtual

Conference. Th presentation included a review of published data from two Phase 2 trials of patients receiving the HAV for vascular access

in hemodialysis, as well as the investigator's personal observations from treating patients requiring vascular access for hemodialysis.

was made by C. Keith Ozaki, M.D., the John A. Mannick Professor of Surgery, Brigham and Women's Hospital/Harvard Medical School,

Vice-Chair, Department of Surgery at the Brigham, and principal investigator of Humacyte's HAV Phase 3 trials in vascular access.

Dr. Ozaki, who has consulted with Humacyte in the past, is also a noted thought leader in the vascular surgery and hemodialysis access

HAV has the potential to overcome many of the limitations seen with traditional conduits such as ePTFE and bovine carotid grafts, notably

the increased risk of infection," said Dr. Ozaki.. Published Phase 2 data have demonstrated the HAV repopulates with the patient's

own vascular cells, reducing the chance of infection and potentially improving patient outcomes. These data, along with the performance

of the HAV in a clinical setting, support the continued evaluation of the HAV in vascular access."

data from Humacyte's Phase 2 clinical trial studying the HAV in hemodialysis demonstrated that the HAV provided long-term durability

and functional access, with a low risk of infection. The potential utility of the HAV in contaminated and/or infected settings and in

arteriovenous reconstructions were highlighted by Dr, Ozaki as particular areas of interest based on the Phase 2 results.

HAV's performance in a clinical setting presented today by Dr. Ozaki highlights the potential of the HAV to be a durable, effective

and safe alternative for vascular access in patients requiring hemodialysis," said Laura Niklason, M.D., Ph.D., Chief Executive

Officer of Humacyte. "The HAV is currently being evaluated in multiple late-stage trials, and we look forward to continuing to

explore the potential of our HAV to address significant unmet needs in vascular access, vascular trauma and peripheral arterial disease."

17, 2021, Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) ("AHAC"), a special purpose acquisition company, and Humacyte

announced the execution of a definitive business combination agreement along with a fully committed $175 million PIPE financing agreement.

Human Acellular Vessels (HAV) are engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction

and replacement. HAV is intended to overcome long-standing limitations in vessel tissue repair and replacement - it can be manufactured

at commercial scale, it eliminates the need for harvesting a vessel from a patient, and clinical evidence suggests that it is non-immunogenic,

infection-resistant, and can become durable living tissue. HAV is currently being evaluated in two Phase 3 trials in AV access and a

Phase 2/3 trial for vascular trauma, and has been used in more than 430 patient implantations. It is the first product to receive Regenerative

Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration, and has also received FDA Fast Track designation.

Humacyte, Inc., is developing a disruptive biotechnology platform

to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the

practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic

conditions. Humacyte's initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials

targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial

disease. Pre-clinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes,

and multiple novel cell and tissue applications. Humacyte's HAVs were the first product to receive the FDA's Regenerative

Medicine Advanced Therapy (RMAT) expedited review designation and received priority designation for the treatment of vascular trauma by

the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

Alpha Healthcare Acquisition Corp.

Alpha Healthcare Acquisition Corp. (ticker: AHAC) is a special purpose acquisition company formed for the purpose of effecting a

business combination with one or more businesses in the healthcare sector ("AHAC"). The company was founded by Mr. Rajiv

Shukla who has two decades of buyouts, investments and operations experience in the healthcare industry. Mr. Shukla previously served

as Chairman and Chief Executive Officer of Constellation Alpha Capital Corp., a Nasdaq-listed special purpose acquisition company,

that merged with DermTech, Inc (ticker: DMTK) in August 2019. On February 17, 2021, AHAC announced a definitive agreement to merge

with Humacyte, Inc. along with a concurrent fully committed PIPE placement of $175 million of AHAC common shares at a price of $10.00

Information About the Merger and Where to Find It

A full description of the terms of the business combination is provided in a registration statement on Form S-4 filed with the SEC

by AHAC that includes a prospectus with respect to the Combined Company's securities to be issued in connection with the business

combination and a proxy statement with respect to the shareholder meeting of AHAC to vote on the business combination. AHAC urges its

investors, shareholders and other interested persons to read, the preliminary proxy statement/ prospectus as well as other documents

filed with the SEC because these documents will contain important information about AHAC, Humacyte and the business combination. After

the registration statement is declared effective, the definitive proxy statement/prospectus included in the registration statement will

be mailed to shareholders of AHAC as of a record date to be established for voting on the proposed business combination. Shareholders

will also be able to obtain a copy of the Form S-4, including the proxy statement/prospectus, and other documents filed with the SEC

without charge, by directing a request to: Alpha Healthcare Acquisition Corp., Attn: Secretary, 1177 Avenue of the Americas, 5th Floor,

New York, New York 10036. The preliminary and definitive proxy statement/prospectus to be included in the registration statement,

can also be obtained, without charge, at the SEC's website (www.sec.gov).

AHAC and Humacyte and their respective directors and executive officers may be considered participants in the solicitation of proxies

with respect to the proposed business combination described in this press release under the rules of the SEC. Information about the directors

and executive officers of AHAC is set forth in AHAC's final prospectus filed with the SEC pursuant to Rule 424(b) of the Securities

Act of 1933, as amended (the "Securities Act") on September 17, 2020, and is available free of charge at the SEC's

website at www.sec.gov or by directing a request to: Alpha Healthcare Acquisition Corp., Attn: Secretary, 1177 Avenue of the Americas,

5th Floor, New York, New York 10036. Information regarding the persons who may, under the rules of the SEC,

be deemed participants in the solicitation of the AHAC shareholders in connection with the proposed business combination will be set

forth in the registration statement containing the proxy statement/prospectus for the proposed business combination. These documents

can be obtained free of charge from the sources indicated above.

This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently

available. In some cases, you can identify forward-looking statements by the following words: "may," "will,"

"could," "would," "should," "expect," "intend," "plan," "anticipate,"

"believe," "estimate," "predict," "project," "potential," "continue,"

"ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain

these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance

or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we

believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these

statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot

be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding the initiation,

timing, progress and results of our clinical trials; the anticipated characteristics and performance of our HAVs, our ability to successfully

complete, clinical trials for our HAVs; the anticipated benefits of our HAVs relative to existing alternatives; the commercialization

of our HAVs and our ability to manufacture at commercial scale; the implementation of our business model, strategic plans for our business;

the scope of protection we are able to establish and maintain for intellectual property rights covering our HAVs and related technology;

the timing or likelihood of regulatory filings and approvals; timing, scope and rate of reimbursement for our HAVs; our estimated available

market opportunity; the proposed business combination, including the timing and structure of the business combination, the proceeds of

the business combination, and the benefits of the business combination. We cannot assure you that the forward-looking statements in this

press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties

that could cause actual results to differ materially from expected results, including, among others, the ability to complete the business

combination due to the failure to obtain approval from AHAC's shareholders or satisfy other closing conditions in the Business

Combination Agreement, the occurrence of any event that could give rise to the termination of the Business Combination Agreement, the

ability to recognize the anticipated benefits of the business combination, the outcome of any legal proceedings that may be instituted

against AHAC or Humacyte following announcement of the proposed business combination and related transactions, the impact of COVID-19

on Humacyte's business and/or the ability of the parties to complete the business combination, the ability to obtain or maintain

the listing AHAC's common stock on Nasdaq following the proposed business combination, costs related to the proposed business combination,

changes in applicable laws or regulations, the possibility that Alpha Healthcare Acquisition Corp. or Humacyte may be adversely affected

by other economic, business, and/or competitive factors, and other risks and uncertainties, including those to be included under the

header "Risk Factors" in the registration statement on Form S-4 filed by AHAC with the SEC and those included under the header

"Risk Factors" in the final prospectus of AHAC related to its initial public offering. Most of these factors are outside

of AHAC's and Humacyte's control and are difficult to predict. Furthermore, if the forward-looking statements prove to be

inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should